{
    "persona": "conservative",
    "model": "llama2:70b-chat-q6_K",
    "topic": "healthcare",
    "language": "English",
    "text": "Great news for migraine sufferers! New data shows atogepant is effective in reducing monthly migraine days by 8.5 days on average, with 70% of patients achieving at least a 50% reduction. This is a game-changer for those who have struggled with this debilitating condition.",
    "retrieved_source": "https://www.medscape.com/viewarticle/first-long-term-data-atogepant-migraine-prevention-2024a10007cb",
    "annotation": {
        "topic": null,
        "persona": null,
        "authenticity": null
    },
    "id": "fd9ae583bcf9ac5673ab5c95c0018ab07de25bf628b85327"
}